An interventional study of Non-invasive glucose meter and EKF analyzer in Diabetes Mellitus, sponsored by Lepu Medical Technology (Beijing) Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-08-30.
Sponsored by Lepu Medical Technology (Beijing) Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 417 studies in Diabetes Mellitus with a site in China — 100 open to participants now, 117 under way, 11 of them phase 3. Diabetes Mellitus · China.
Among the 417 studies in Diabetes Mellitus with a site in China, this one is the 113th largest by enrollment of the 280 interventional ones that give a count, is one of 36 that started in 2022, is one of 118 with no phase, and was the 295th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →100 of the 417 studies in Diabetes Mellitus with a site in China are open now. Recruiting first, the newest first:
China Medical University, China · Sites in China
Ages 50–75
CSL Behring · Sites in China
Ages 18+
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
417 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 25 · Phase 3 41 · Phase 4 52
First in 2002; this study’s year is marked. 36 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 143 across the 280 interventional studies, 605 across the 137 observational. Of the 204 that completed or were terminated, 47 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 417 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lepu Medical Technology (Beijing) Co., Ltd., one of the names counted as Lepu Medical. Under that name alone:
Lepu Medical Technology (Beijing) Co., Ltd. is the lead sponsor of 15 studies on the registry; 4 are open to participants now.
Lepu Medical has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
19 of the studies in Diabetes Mellitus with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06309082First Affiliated Hospital of Wenzhou Medical UniversityAssessing Diabetic Foot Ulcer Microcirculation With High-frequency Contrast Enhanced Ultrasound | 2026-12 |
| NCT05105321Tang YidaCardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP) | 2026-12 |
| NCT07489482Jiangsu HengRui Medicine Co., Ltd.A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection | 2026-12 |
| NCT06959784China-Japan Friendship HospitalAssessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) | 2026-12-31 |
| NCT06958640China-Japan Friendship HospitalDa Qing Offspring Study | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 417 studies in Diabetes Mellitus with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a prospective, multicenter, open-label, self-controlled study to evaluate the efficacy and safety of multi-parameter non-invasive glucose meters for blood glucose measurement,planned enrollment of 200 patients with type 1 or type 2 diabetes.
Comparing glucose measurements from the Non-Invasive Glucose monitoring system to venous blood glucose or fingertip blood glucose to evaluate System accuracy capability.
At the same time, blood glucose was measured by non-invasive blood glucose meter, Accu-Chek Guide blood glucose meter and EKF Biosen C-Line. Eight groups of blood glucose values were collected from each subject during fasting, after breakfast and after lunch.After the end of blood glucose measurement, the data were recorded, including adverse events and device defects during the test. The subjects were required to stay in the examination room for 5-10 minutes, during which they completed the product use evaluation questionnaire.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The noninvasive glucose meter was entrained on the finger, Glucose concentration levels were measured by measuring physiological parameters related to metabolic heat and local oxygen supply.
Device: Non-invasive glucose meter
Being used for quantitative determination of blood glucose concentration in fresh capillary whole blood taken from fingers.
Device: Accu-Chek Guide
Using the hexosyl enzymatic method to detect plasma glucose values
Device: EKF analyzer
Blood glucose levels were measured while fasting, after breakfast, and after lunch,Place your index finger into the non-invasive blood glucose meter and wait for the instrument to display the reading.
Blood glucose levels were measured while fasting, after breakfast, and after lunch,After collecting venous blood and separating plasma, blood glucose detection is performed using the EKF analyzer with the hexokinase method.
Blood glucose levels were measured while fasting, after breakfast, and after lunch,Use Accu-Chek Guide blood glucose meter to prick the finger and obtain blood for glucose measurement
The results were analyzed by consensus error grid (CEG)
The proportion of the results lie within zone A and zone B of the consensus error grid (CEG)
Time frame: After 2 days of blood glucose measurements
Mean Absolute Relative Difference (MARD)
It is calculated by taking the absolute difference between the two values, dividing it by their average. A smaller MARD value indicates a smaller relative difference between the two values, indicating higher consistency between them.
Time frame: The day after the blood glucose measurement
The 20/20% agreement rates
the proportion of Non-invasive blood glucose values that were within 20% of paired reference blood glucose values \>80 or 20 mg/dL of reference blood glucose values ≤100 mg/dL
Time frame: The day after the blood glucose measurement
Accessibility evaluation Questionnaire for non-invasive glucose meter
The questionnaire covers the subjects' self-monitoring of blood glucose status, their awareness and expectations of non-invasive testing, as well as their subjective feelings after using a non-invasive blood glucose meter.
Time frame: The day after the blood glucose measurement
Ran from Sep 2022 to primary completion in Jul 2023, 9 months.
Of 160 industry-sponsored interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 9 months is below that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lepu Medical Technology (Beijing) Co., Ltd. →